Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Completed 8Active not recruiting 3Terminated 2Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 3NET 2Genitourinary 2Gastrointestinal 2Breast 2Head & Neck 1

Conditions

Serotonin Syndrome 1Neuroendocrine Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1Acromegaly 1

Interventions

Everolimus 7lutetium Lu 177 dotatate 3lanreotide 3Erlotinib Hydrochloride 3surufatinib 2gallium Ga 68 dotatate 2dactolisib 2Sunitinib 2Octreotide 2Magnetic Resonance Spectroscopy 2Filgrastim 2Capecitabine 2trifluridine tipiracil drug combination 1tislelizumab 1telotristat ethyl 1telotristat 1pertuzumab 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1fosbretabulin 1folfirinox 1famitinib 1entinostat 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1alectinib 1Temozolomide 1Surveys and Questionnaires 1Somatostatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Octreotide × NET × Clear all
NCT05364944 2025-11-17

OXTEND-01

Debiopharm International SA

Phase 1 Terminated
19 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Acromegaly

NCT04140409 2019-10-25

SCIROCCO

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 4 Terminated
10 enrolled
EndocrineNET

Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡